Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
A 70 years old female patient received a dose of Arexvy in 2023 and this year the patient received a second dose of Arexvy.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 70-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Previously administered products included Arexvy (received 1st dose in 2023 ). On an unknown date, the patient received the 2nd dose of Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: A 70 years old female patient received a dose of Arexvy in 2023 and this year the patient received a second dose of Arexvy.). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 31-JAN-2025 The patient received Arexvy in 2023 and now in reporting year the patient received a second dose of Arexvy, which led to extra dose administered. The reporter wanted to know if they had any studies regarding this situation or was there any concern for possible adverse reactions.